These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36000489)

  • 1. Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.
    Brownlee WJ; Wolf C; Hartung HP; Dingermann T; Anshasi N; Clark RA; Trojano M; Selmaj K; Uitdehaag BM; Tur C; Wuerfel J; Dallmann G; Witte J; Sintzel M; Bobrovnikova O; Cohen JA
    Mult Scler; 2022 Dec; 28(14):2177-2189. PubMed ID: 36000489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Rae-Grant A; Day GS; Marrie RA; Rabinstein A; Cree BAC; Gronseth GS; Haboubi M; Halper J; Hosey JP; Jones DE; Lisak R; Pelletier D; Potrebic S; Sitcov C; Sommers R; Stachowiak J; Getchius TSD; Merillat SA; Pringsheim T
    Neurology; 2018 Apr; 90(17):777-788. PubMed ID: 29686116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
    Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
    Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.
    Brieva L; Estruch BC; Merino JAG; Meca-Lallana V; Río J; Rodríguez-Antigüedad A; Agüera E; Ara JR; Luque AA; Garcia CA; Blanco Y; Castillo-Triviño T; Costa-Frossard L; González Platas M; Pascual LL; Llaneza-González M; Ginés MLM; Matías-Guiu J; Meca-Lallana JE; Bilbao MM; Sempere AP; Romero-Pinel L; Saiz A; Moral E
    Mult Scler Relat Disord; 2022 Jul; 63():103805. PubMed ID: 35512501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients experiences with multiple sclerosis disease-modifying therapies in daily life - a qualitative interview study.
    Sippel A; Riemann-Lorenz K; Scheiderbauer J; Kleiter I; Morrison R; Kofahl C; Heesen C
    BMC Health Serv Res; 2021 Oct; 21(1):1141. PubMed ID: 34686166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
    Otero-Romero S; Lebrun-Frénay C; Reyes S; Amato MP; Campins M; Farez M; Filippi M; Hacohen Y; Hemmer B; Juuti R; Magyari M; Oreja-Guevara C; Siva A; Vukusic S; Tintoré M
    Eur J Neurol; 2023 Aug; 30(8):2144-2176. PubMed ID: 37293849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
    Otero-Romero S; Lebrun-Frénay C; Reyes S; Amato MP; Campins M; Farez M; Filippi M; Hacohen Y; Hemmer B; Juuti R; Magyari M; Oreja-Guevara C; Siva A; Vukusic S; Tintoré M
    Mult Scler; 2023 Jul; 29(8):904-925. PubMed ID: 37293841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barriers to accessing multiple sclerosis disease-modifying therapies in the Middle East and North Africa region: A regional survey-based study.
    Zeineddine M; Al-Hajje A; Salameh P; Helme A; Thor MG; Boumediene F; Yamout B
    Mult Scler Relat Disord; 2023 Nov; 79():104959. PubMed ID: 37651815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating patients' preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review.
    Ngorsuraches S; Poudel N
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):183-195. PubMed ID: 33472451
    [No Abstract]   [Full Text] [Related]  

  • 11. Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States.
    Bin Sawad A; Seoane-Vazquez E; Rodriguez-Monguio R; Turkistani F
    Curr Med Res Opin; 2016 Nov; 32(11):1783-1788. PubMed ID: 27359262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis.
    Filippi M; Danesi R; Derfuss T; Duddy M; Gallo P; Gold R; Havrdová EK; Kornek B; Saccà F; Tintoré M; Weber J; Trojano M
    J Neurol; 2022 Mar; 269(3):1670-1677. PubMed ID: 34626224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethical use of off-label disease-modifying therapies for multiple sclerosis.
    Laurson-Doube J; Rijke N; Helme A; Baneke P; Banwell B; Viswanathan S; Hemmer B; Yamout B
    Mult Scler; 2021 Aug; 27(9):1403-1410. PubMed ID: 34304636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA.
    Hartung DM
    Curr Neurol Neurosci Rep; 2021 May; 21(7):28. PubMed ID: 33948740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expert opinion on the use of contraception in people with multiple sclerosis.
    Hillert J; Bove R; Haddad LB; Hellwig K; Houtchens M; Magyari M; Merki-Feld GS; Montgomery S; Nappi RE; Stenager E; Thompson H; Tulek Z; Verdun Di Cantogno E; Simoni M
    Mult Scler; 2024 Mar; ():13524585241228103. PubMed ID: 38456514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hiding in plain sight: The magnitude of unused disease modifying therapies in multiple sclerosis and strategies for reducing the economic burden of care.
    Okuda DT; Burgess KW; Cook K; McCreary M; Winkler MD; Moog TM
    Mult Scler Relat Disord; 2022 Jul; 63():103920. PubMed ID: 35661567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward a Shared-Care Model of Relapsing-Remitting Multiple Sclerosis: Role of the Primary Care Practitioner.
    Oh J; Gagné-Brosseau MS; Guenette M; Larochelle C; Lemieux F; Menon S; Morrow SA; Poliquin-Lasnier L; Roy-Hewitson C; Rush C; Trudelle AM; Giacomini PS
    Can J Neurol Sci; 2018 May; 45(3):304-312. PubMed ID: 29756588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America.
    Burt RK; Tappenden P; Han X; Quigley K; Arnautovic I; Sharrack B; Snowden JA; Hartung D
    Mult Scler Relat Disord; 2020 Oct; 45():102404. PubMed ID: 32731201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
    Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
    Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.